re: the holy grail So my mail two years ago looks like proving good, I was told it could be a $2 share within the first 6 weeks of commercialisation.....now even that looks conservative.Worth the waitHQ
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
